Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson’s Disease: New Perspectives to a Long-Standing Model

• Autor(a) principal: Leão, Anderson H.F.F.
• Data de Publicação: 2015
• Outros Autores: Sarmento-Silva, Aldair J., Santos, José R., Ribeiro, Alessandra M., Silva, Regina H.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRN
• Texto Completo: https://repositorio.ufrn.br/jspui/handle/123456789/19023
• topic: animal model; dopamine; Parkinson’s disease; reserpine; rodent

he administration of reserpine to rodents was one of the first models used to investigate the pathophysiology and screening for potential treatments of Parkinson’s disease (PD). The reserpine model was critical to the understanding of the role of monoamine system in the regulation of motor and affective disorders, as well as the efficacy of current PD treatments, such as L-DOPA and dopamine agonists. Nevertheless, with the introduction of toxin-induced and genetic models of PD, reserpine became underused. The main rationale to this drawback was the supposed absence of reserpine construct validity with PD. Here, we highlight classical and recent experimental findings that support the face, pharmacological, and construct validity of reserpine PD model and reason against the current rationale for its underuse. We also aim to shed a new perspective upon the model by discussing the main challenges and potentials for the reserpine model of PD.